Table 3.
Simple Logistic Regression Analysis Evaluating Risk of PCP
| Variable | Comparison | Odds Ratios (95% CI) | P value |
|---|---|---|---|
| Age | Increase by 1 year | 0.93 (.81, 1·07) | .30 |
| Sex | Female vs male | 0.67 (.22, 1.99) | .47 |
| Race | White vs other | 0.18 (.04, .87) | .033 |
| Duration between transplant and PCP diagnosis | Increase by 1 month | 1.20 (.91, 1.58) | .20 |
| Donor Type | Deceased donor vs living donor | 1.32 (.36, 4.80) | .67 |
| Induction immunosuppression | Non-steroids vs steroids | 1.00 (.05, 18·91) | 1.00 |
| TCMR within 90 days of PCP diagnosis | Yes vs no | 2.00 (.28, 14.20) | .49 |
| Belatacept | Yes vs no | 4.67 (1.21, 18·05) | .026 |
| mTOR inhibitor | Yes vs no | 0.67 (.07, 6.41) | .73 |
| Antiproliferative agent | Yes vs no | 2.14 (.43, 10.71) | .36 |
| MMF total daily dose | Increase by 500 mg | 1.24 (.87, 1.77) | .24 |
| Number of transplant clinic visits within 180 days of PCP diagnosis | Increase by 1 day | 1.31 (1.06, 1.63) | .012 |
| Receipt of prednisone ≥ 20mg/day for ≥ 2 weeks within 90 days of PCP diagnosis | Yes vs no | 2.00 (.28, 14.20) | .49 |
| Absolute Lymphocyte Count (cells/μL) at PCP diagnosis | Decrease by 100 cells/μL | 1.11 (1.01, 1.22) | .028 |
Abbreviations: CI, confidence interval; MMF, mycofenolate mofetil; mTOR, mechanistic target of rapamycin; PCP, Pneumocystis jirovecii pneumonia; TCMR: T-cell-mediated rejection.